Mechanisms of prostate cancer recurrence during androgen deprivation are poorly understood. We recently described androgen receptor (AR) gene ampli®-cation in 28% of recurrent prostate carcinomas from hormone-refractory prostate cancer patients. To investigate the hypothesis that ampli®cation of the AR gene promotes the growth of hormone-refractory prostate carcinomas, DNA¯ow cytometric (FCM) studies were carried out to compare matched, primary and hormone-refractory recurrent samples from 31 prostate cancer patients. Recurrent tumours had a higher (P 0.05) S-phase fraction (SPF) (10.6 AE 4.6) than corresponding primary tumours from the same patients (7.0 AE 4.1) and the frequency of aneuploidy also increased from 8±55%. Recurrent tumours with AR gene ampli®cation had a signi®cantly higher (P 0.02) SPF (14.0 AE 6.5) than those with no ampli®cation (9.0 AE 2.9). The results suggest that clinical progression of prostate cancer during androgen withdrawal therapy is often associated with increased cell proliferation rate and formation of DNA aneuploidy. AR ampli®-cation may be an important molecular mechanism underlying the increase in proliferation rate of some recurrent tumours.
Introduction
About 70±80% of patients with metastatic prostate cancer show a favourable primary response to androgen deprivation therapy. However, eventually most of the carcinomas treated by androgen deprivation progress despite of the therapy. There are no effective treatment options for hormone-refractory prostate cancer and prognosis after relapse remains poor. 1 Very little is known on molecular mechanisms that underlie treatment failure during androgen deprivation. Most of the studies have focused on the possible role of the altered structure or function of the androgen receptor gene in mediating development of hormone-refractory cell growth. 2±6 The strategy of our laboratory to study molecular mechanisms that underlie progression of prostate cancer during androgen deprivation has been to compare genetic changes in paired specimens from primary and recurrent tumours taken from patients before endocrine therapy as well as after failure of the therapy. Using paired specimens, changes that are related to tumour progression and treatment failure can be identi®ed. For example, we recently analysed the tumours for AR gene copy number by¯uorescence in situ hybridization (FISH) and found that 15 out of 54 recurrent tumours (28%) showed AR gene ampli®cation. 7 We also postulated that this ampli®cation provided a selective advantage for prostate cancer cells growing in an androgen-de®cient environment and possibly lead to androgen hypersensitivity of the tumour cells.
The aim of this study was to investigate whether such a selection process leading to AR ampli®ed tumours also results in increased cell proliferation activity of the tumours. Furthermore, direct comparisons were made between the percentage of aneuploidy, which means loss or gain of one or more chromosomes, and the rate of proliferation in paired samples from untreated primary tumours and in the hormonally-treated, locally recurrent prostate carcinomas from the same patients.
Materials and Methods

Samples
The material consisted of 31 prostate cancer patients treated by conventional androgen deprivation (orchiectomy 27 cases, luteinizing hormone releasing hormoneÐ agonist three cases, luteinizing hormone releasing hormone Ð agonist and oestrogen one case) in the Tampere University Hospital between 1972±1994. All patients experienced a local tumour recurrence, as evidenced by symptoms of urethral obstruction and an increase of serum prostatic acid phosphatase (prior to the 1991) or serum prostate speci®c antigen levels (after 1991). Primary tumour specimens taken before therapy were available from only 12 (eight transurethral resection specimens, four Tru-Cut needle biopsies) patients and locally recurrent tumour specimens from all 31 patients (®ve Tru-Cut needle biopsies, 26 transurethral resection specimens). Altogether, there were 12 primary-recurrent tumour sample pairs from the same patients.
Representative formalin-®xed, paraf®n-embedded tumour blocks were selected by histopathological examination of haematoxylin and eosin-stained slides. Primary tumours were staged according to TNM classi®cation 8 and histological grading was done according to World Health Organisation recommendations. 9 The clinical data are presented in Table 1 .
DNA¯ow cytometry
Fifty micrometer sections for FCM analysis were cut from representative (containing more than 60% of malignant tissue) paraf®n-embedded tumour blocks that were selected by examination of haematoxylin and eosinstained slides. Nuclear suspensions for FCM analysis were prepared as described in more detail elsewhere. 10, 11 Brie¯y, sections were deparaf®nized with xylene, rehydrated in an ethanol series and placed in Carlsberg± proteinase (proteinase XXIV; Sigma Chemical Corporation, St. Louis, MO) for 1 h at 37 C. The nuclear suspensions were stained with 50 mgaml ethidium bromide (Sigma) followed by RNAase treatment and analysed with EPICS-C¯ow cytometer (Coulter Electronics Inc., Hialeah, FL). Cell cycle distributions were analysed with the MultiCycle Software program (Phoenix Flow Systems, San Diego, CA) using sliced nuclei background correction as described earlier.
11 DNA aneuploidy was considered to be present if two clearly separate peaks were found in DNA histograms (DNA-index b 1.05). In aneuploid cases only the SPF of the aneuploid clone was recorded. Cell cycle distribution was not considered evaluable if the cell cycle distribution of the diploid and aneuploid clones overlapped heavily or if a very small aneuploid clone (`25%) was present. The mean coef®-cient of variation (CV) of the diploid G 0 aG 1 peaks was 8.6% AE 1.3%.
Statistical analysis
Statistical analyses were performed using the BMDP Statistical Software Package.
12 S-phase of primary and recurrent tumours were compared with paired t-test. Clinicopathological correlations, as well as ploidy results, were analysed using Fisher's exact test. All results are expressed as mean AE standard deviation.
Results
FCM analysis of DNA ploidy and DNA index was successful in all cases evaluated, whereas S-phase was evaluable in 7 out of 9 (78%) primary tumours and 18 out of 22 (82%) recurrences.
Only 1 out of 12 (8%) untreated primary tumours were DNA aneuploid. In contrast, the frequency of DNA aneuploidy in all hormonally treated, locally recurrent tumours was 17 out of 31 (55%) (Figure 1) , and 8 out of 12 (67%) in those 12 recurrent tumours having corresponding primary tumours from the same patients ( Table 2) . The SPF was also higher (P 0.05) in the recurrent (10.6 AE 4.6) than in the untreated primary tumours (7.0 AE 4.1) (Figure 1 ), and even (P 0.01) higher (11.8 AE 4.5) in those 12 hormonally-treated recurrent tumours.
Recurrent tumours with AR gene ampli®cation were particularly often (89%) DNA aneuploid (P 0.006) as compared to recurrent tumours with no ampli®cation (32%) (Figure 1 ). Tumours ampli®ed for AR had a higher (P 0.02) proliferative activity measured by SPF (14.0 AE 6.5) than recurrent tumours with no ampli®cation (9.0 AE 2.9) (Figure 1 ).
Discussion
Total nuclear DNA content is a rough estimate of the number of numerical chromosomal aberrations. A large number of studies have been published on the prognostic value of DNA¯ow cytometric SPF and ploidy levels in primary prostate cancer. 13, 14 In this study the aim was to compare the DNA¯ow cytometric ®ndings in untreated primary prostate cancers with corresponding hormonally treated, locally recurrent prostate carcinoma specimens from the same patients. Both the frequency of DNA aneuploidy and the fraction of S-phase cells (SPF) were signi®cantly higher in tumours that had progressed during endocrine therapy. This suggests that these recurrent tumours are probably genetically more evolved than the corresponding primary tumours. This observation is concordant with the clinical ®ndings of a poor prognosis of patients after relapse during endocrine treatment. 15 Androgen withdrawal initially decreases cell proliferation of both normal and malignant prostate epithelial cells. 16, 17 A large fraction of cells undergo apoptotic death. However, after a variable period of time on androgen deprivation, a small tumour cell clone evolves, begins to grow again, progresses and ®nally a recurrent tumour arises that is resistant to androgen deprivation. The mechanism underlying this progression have remained poorly understood, but androgen receptor gene is likely to be involved. Tumour cells with mutations of the AR gene may enable transactivation of the AR by other steroids than the usual ligand dihydrotestosterone. 2, 18 Furthermore, we recently found ampli®cation of the AR gene in about one third of tumours recurring during androgen deprivation. 19 The ®nding in the present study that recurrent tumours with AR ampli®cation were more highly proliferative, and more often aneuploid than their counterparts with no AR ampli®cation supports the signi®cance of AR gene ampli®cation in tumour recurrence and endocrine therapy failure. AR ampli®ed recurrent tumours are thus likely to be the most genetically unstable of all recurrent tumours. This may re¯ect the fact that gene ampli®cation can only occur in genetically unstable cells. 20, 21 AR ampli®cation also is associated with increased SPF. This indicates that AR mediated cell proliferation can be augmented in the recurrent tumour cells.
Preliminary studies indicate that AR ampli®cation in the recurrent tumours is not directly associated with the prognosis of the patients following androgen deprivation therapy failure. To consolidate this ®nding with the present ®nding of a high SPF and aneuploid rate, we hypothesise that AR ampli®ed tumours remain hormonally regulated and therefore more differentiated even though they are proliferatively active and genetically Table 2 The DNA¯ow cytometric data from untreated primary and hormone-refractory recurrent tumour sample pairs from the 12 patients unstable. Their response to secondary hormonal therapy (such as maximal androgen blockade) may also be favourable. 22 
Conclusions
These results demonstrate that aneuploidy and cell proliferation are increased during the progression of prostate cancers from untreated primary to hormonally treated, locally recurrent ones. Genetic instability in a subset of prostate carcinomas may also be increased, which then enables these tumours to achieve properties, namely AR gene ampli®cation, that allow them to grow in the low levels of androgens and cause tumour progression. These observations may give background for novel therapeutic strategies, for example, combined hormonal and cytotoxic drugs as a second-line therapy in patients with high SPF, because the cell proliferation rate of hormone-refractory prostate carcinomas is much higher than suggested by the proliferation measurements of primary tumour samples.
